Propofol
Propofol Baxter contains the active substance propofol. Propofol Baxter belongs to a group of medicines called general anesthetics. It is used to induce and maintain general anesthesia (deep sleep) to enable surgery or other procedures to be carried out.
Before starting treatment with Propofol Baxter, discuss with your doctor, anesthesiologist, or nurse:
After taking Propofol Baxter, you may experience its effects. You should not leave the hospital alone.
Propofol Baxter should not be used in children under 3 years of age, as the recommended gradual administration of Propofol Baxter to small children is a difficult task due to the extremely small volume required.
In elderly patients, smaller doses of Propofol Baxter are required for induction of anesthesia. The dose should be adjusted according to the patient's overall health and age. A reduced dose should be administered more slowly and titrated according to the patient's response.
Tell your doctor about all medicines you are taking, or have recently taken, and any you plan to take.
Do not drink alcohol in any form after taking Propofol Baxter.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
After taking propofol, you may still feel sleepy for some time. Do not drive or use tools or machines until the effects of the medicine have worn off.
Propofol Baxter contains soybean oil. Do not use if you have a known allergy to peanuts or soybeans.
This medicine contains less than 1 mmol of sodium (23 mg) per vial, which is essentially sodium-free.
Propofol Baxter will be given to you by injection or infusion into a vein, usually on the back of your hand or forearm.
The dose of Propofol Baxter used will depend on your age, weight, overall health, and any other medicines you are taking. Your doctor will decide the dose and monitor your response to the medicine.
Like all medicines, Propofol Baxter can cause side effects, although not everybody gets them.
When given together with lidocaine, the following side effects may rarely occur:
If you experience any side effects, talk to your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw
Tel.: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.
Store in a temperature not exceeding 25°C.
Do not freeze.
After first opening, the product should be used immediately.
Shake before use.
Do not use this medicine if you notice two layers after shaking.
Only use homogeneous solutions and undamaged vials.
For single use only. Unused emulsion should be discarded.
The anesthesiologist and pharmacist are responsible for the proper storage, use, and disposal of Propofol Baxter.
The active substance is propofol.
1 ml of emulsion for injection/infusion contains 20 mg of propofol.
A 50 ml vial contains 1000 mg of propofol.
The other ingredients are purified soybean oil, medium-chain triglycerides, glycerol, egg lecithin, sodium oleate, sodium hydroxide (for pH adjustment), and water for injections.
White oil-in-water emulsion for injection/infusion.
Propofol Baxter is available in:
Emulsion for injection/infusion in a colorless glass vial (type II) with a gray rubber stopper.
Pack sizes:
50 ml colorless glass vial (type II) with a gray rubber stopper, pack containing 1 and 10 vials.
Not all pack sizes may be marketed.
Baxter Holding B.V.
Kobaltweg 49,
3542CE Utrecht, Netherlands
Baxter Holding B.V.
Kobaltweg 49,
3542CE Utrecht, Netherlands
Baxter Healthcare Limited
Caxton Way
Thetford, Norfolk IP24 3SE, United Kingdom
UAB Norameda, Vilnius, Lithuania
Bieffe Medital S.p.A.,
Via Nuova Provinciale
23034 Grossotto (SO), Italy
Country | Trade names |
Germany (RMS) | Propofol Baxter 20 mg/ml MCT Emulsion zur Injektion/Infusion |
Austria | Propofol Baxter 2 % (20 mg/ml) MCT Emulsion zur Injektion/Infusion |
Czech Republic | Anesia 20 mg/ml injekční/infuzní emulze |
Denmark | Profast 20mg/ml, injektions- og infusionsvæske, emulsion |
Estonia | Anesia |
Finland | Profast 20 mg/ml injektio-/infuusioneste, emulsio |
France | PROPOFOL BAXTER 20 mg/ml, emulsion injectable/pour perfusion |
Hungary | Anesia 20 mg/ml emulziós injekció vagy infúzió |
Ireland | Propofol 20mg/ml Emulsion for Injection/infusion |
Italy | Rapiva 20 mg/ml emulsione iniettabile e per infusion |
Latvia | Anesia 20 mg/ml emulsija injekcijām/infūzijām |
Lithuania | Anesia 20 mg/ml injekcinė/infuzinė emulsija |
Netherlands | Propofol Spiva 20 mg/ml, emulsie voor injectie of infusie |
Norway | Profast 20 mg/ml injeksjons-/infusjonsvæske, emulsjon |
Poland | Propofol Baxter, 20mg/ml, emulsja do wstrzykiwań/ do infuzji |
Portugal | Propofol Baxter 20 mg/ml emulsão injectável ou para perfusão |
Romania | Profast 20 mg/ml emulsie injectabila/perfuzabila |
Sweden | Profast 20 mg/ml injektionsvätska/infusionsvätska, emulsion |
Slovenia | Anesia 20 mg/ml emulzija za injiciranje ali infundiranje |
United Kingdom | Propofol 20 mg/ml Emulsion for injection/infusion |
---------------------------------------------------------------------------------------------------------------------
This package leaflet is a shortened version of the Summary of Product Characteristics (SPC).
Propofol Baxter may only be administered by persons with appropriate expertise in the use of anesthetic drugs, in a setting where full facilities for monitoring and maintenance of the patient are available.
Chemical and physical stability have been demonstrated for 12 hours at 25°C.
Use immediately after opening.
For single use only. Discard any unused product.
Before administration, the rubber stopper of the vial should be disinfected using alcohol spray or an alcohol swab.
The vials should be shaken before use.
Propofol Baxter should be administered by injection or infusion into a vein, using glass vials or plastic syringes.
Propofol Baxter does not contain any antimicrobial preservatives and may be a potential vehicle for microbial growth.
General anesthesia in adults
Induction of anesthesia
Propofol Baxter should be administered slowly (at a rate of 20-40 mg propofol per 10 seconds) until the clinical signs of induction are achieved.
The required dose is usually 1.5-2.5 mg propofol per kg body weight.
Maintenance of anesthesia
Maintenance of general anesthesia can be achieved by administering Propofol Baxter as a continuous infusion.
The dose and rate of infusion should be adjusted according to the patient's response.
General anesthesia in children over 3 years of age
Induction of anesthesia
Propofol Baxter should be administered slowly and carefully until clinical signs of anesthesia are achieved.
The required dose is usually 2.5-4 mg propofol per kg body weight.
Maintenance of anesthesia
Maintenance of anesthesia can be achieved by administering Propofol Baxter as a continuous infusion.
The required dose is usually in the range of 9-15 mg propofol per kg body weight per hour.
Sedation in adults during surgical and diagnostic procedures
During administration of Propofol Baxter, the patient should be continuously monitored for signs of hypotension, airway obstruction, and hypoxia, and standard resuscitative equipment should be available.
For induction of sedation, a dose of 0.5-1.0 mg propofol per kg body weight over 1-5 minutes is usually required.
For maintenance of sedation, the dose should be adjusted according to the level of sedation required and is usually in the range of 1.5-4.5 mg propofol per kg body weight per hour.
Sedation in children over 3 years of age during surgical and diagnostic procedures
The dose and rate of administration should be adjusted according to the level of sedation required and the patient's response.
A dose of 1-2 mg propofol per kg body weight is usually required to induce sedation.
Maintenance of sedation can be achieved by administering Propofol Baxter as a continuous infusion, usually in the range of 1.5-9 mg propofol per kg body weight per hour.
Overdose may lead to cardiovascular and respiratory depression.
Respiratory depression requires artificial ventilation.
In case of cardiovascular depression, standard measures to reduce the position of the head and/or substitute blood volume and vasoconstrictor agents should be taken.
Propofol Baxter should not be used for more than 7 days.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.